2019 Voluntary Scheme

Executive Summary

Pharmaceutical companies in the UK are subject to regulation managing their growth. This ensures the NHS is able to afford the medicines it needs for its patients, while also allowing companies some level of profit and growth. In 2019, two new programmes for managing companies’ growth come into effect: the Statutory Scheme (replacing the Statutory Regulations) and the Voluntary Scheme (replacing the voluntary PPRS).

Key developments in the 2019 Voluntary Scheme include changes to the products included, changes to the repayment percentages required, clarifications on exemptions, and a change around modulation. Read this page to find out more.